We're developing powerful new medicines with the goal of addressing metabolic dysregulation by safely reprogramming cellular physiology with unprecedented multifactorial effects.
Our innovative paradigm integrates preclinical and human signal seeking and confirming studies* to understand the impact of AXA candidates on human biology. Our platform has produced a rich pipeline of AXA candidates which can potentially target multiple indications.
*Axcella conducts pre-IND, IRB-approved studies to evaluate the safety and tolerability of its AXA products in human subjects, or the product’s effects on the normal structure or function of the body. Therapeutic claims would need to be established under IND.
It is widely recognized that metabolism is a core driver of many diseases. AXA™ candidates are designed to leverage the diversity and synergy of amino acid biology and are intended to restore health across a network of dysregulated pathways.
